NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care

$1,302,199U10FY2018CANIH

Dana-Farber Cancer Inst, Boston MA

Investigators

Harold John Bursteincontact Adam S Kibel David P Ryan

Linked publications & trials

Paper 39367245 Paper 39283025 Paper 38688766 Paper 38017103 Paper 36117191 Paper 35792553 Paper 35788257 Paper 35641198 Paper 35420672 Paper 35191970 Paper 35176136 Paper 34311345 Paper 34261293 Paper 33849913 Paper 33707112 Paper 33654204 Paper 33637626 Paper 33426464 Paper 33277314 Paper 33258687 Paper 33049054 Paper 32807727 Paper 32770247 Paper 32758030 Paper 32463741 Paper 32259016 Paper 32092139 Paper 32031887 Paper 31880964 Paper 31852811 Paper 31802506 Paper 31765263 Paper 31668825 Paper 31654784 Paper 31548349 Paper 31418130 Paper 31413100 Paper 31408415 Paper 31399500 Paper 31375516 Paper 31365801 Paper 31361535 Paper 31339827 Paper 31276981 Paper 31216227 Paper 31171508 Paper 31104167 Paper 31073153 Paper 31042420 Paper 30975921 Paper 30916608 Paper 30865548 Paper 30826660 Paper 30737482 Paper 30726946 Paper 30723894 Paper 30688523 Paper 30658992 Paper 30623420 Paper 30567725 Paper 30501481 Paper 30409792 Paper 30291333 Paper 30260474 Paper 30204536 Paper 30146695 Paper 30038051 Paper 30037817 Paper 30030269 Paper 30024889 Paper 29991495 Paper 29872168 Paper 29789969 Paper 29602735 Paper 29563537 Paper 29550566 Paper 29522362 Paper 29489429 Paper 29475737 Paper 29455298 Paper 29384722 Paper 29358223 Paper 29311117 Paper 29261442 Paper 29233548 Paper 29081880 Paper 29034366 Paper 28976791 Paper 28948213 Paper 28945884 Paper 28935272 Paper 28917648 Paper 28842510 Paper 28826616 Paper 28825227 Paper 28807367 Paper 28756902 Paper 28750659 Paper 28653250 Paper 28646344

Abstract

DESCRIPTION (provided by applicant): The overall goal of this application is for Farber/Partners Cancer Care (DF/PCC) to serve as a Lead Academic Participating Site in NCTN and become a leading contributor to NCTN activities. DF/PCC is a joint venture focused on conducting clinical trials and clinical investigator training by across three Harvard- affiliate institutions: Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Massachusetts General Hospital. All are national leaders in cancer clinical research and work cohesively through a well- established unified clinical trials program. Specific aims are: provide leaders to develop and conduct clinical trials, and support NCTN through substantial, robust accrual. While DF/PCC will have as its primary affiliation the Alliance Network Group, faculties will continue their strong historical relationships with a variety of Network Groups. Through a multiple PD/PI model, an engaged interdisciplinary faculty, and a strong operational infrastructure, DF/PCC will provide senior scientific input to trial development trials; identify novel trials to be brought to NCTN; prioritize NCTN trials within our clinical trials portfolio; assure timely activation; provid training and mentoring; distribute funding fairly; and ensure adherence at participating sites. DF/PCC will impact NCTN, which will define new standards of care for adult patients with cancer through 1) scientific leadership in the Steering Committees; 2) participation in CIRB; 3) executive and committee leadership and membership; 4) executive and committee leadership, as well as committee membership; 5) serving as affiliated PIs; 6) leadership in accrual; and 7) training a new generation to participate in the national clinical trials network enterprise.

View original record on NIH RePORTER →